Literature DB >> 7937533

Chemical pathways of peptide degradation. VII. Solid state chemical instability of an aspartyl residue in a model hexapeptide.

C Oliyai1, J P Patel, L Carr, R T Borchardt.   

Abstract

The chemical stability of an Asp-hexapeptide (Val-Tyr-Pro-Asp-Gly-Ala) in lyophilized formulations was evaluated as a function of multiple formulation variables--specifically pH of the bulk solution, temperature, moisture content, and type of bulking agent (amorphous vs. crystalline). The disappearance of the starting Asp-hexapeptide in the solid state conformed to pseudo-first-order reversible kinetics. This type of degradation profile was accounted for by the product distribution. The factorial experimental design of this study allowed statistical analysis of the effects of individual formulation variable (main effects) as well as those of two-factor interactions on the degradation of the Asp-hexapeptide. Analysis of Variance (ANOVA) calculations of the main effects indicated that while the influence of pH of the starting solution was not statistically significant, residual moisture level, temperature, and, especially, type of bulking agent had a significant impact on the solid state chemical reactivity of the hexapeptide. Furthermore, depending on which type of excipient was used in the lyophilized formulations, residual moisture level and temperature could be important stability variables. These types of factorial experiments have proven to be useful in the rapid identification of significant formulation variables in a given system and, consequently, in optimization of formulations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937533     DOI: 10.1023/a:1018998312503

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides.

Authors:  K Patel; R T Borchardt
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

Review 2.  Pharmaceutics of protein drugs.

Authors:  R Pearlman; T Nguyen
Journal:  J Pharm Pharmacol       Date:  1992-02       Impact factor: 3.765

3.  Mechanical activation of pharmaceutical systems.

Authors:  R Hüttenrauch; S Fricke; P Zielke
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

4.  An unexpected pH effect on the stability of moexipril lyophilized powder.

Authors:  R G Strickley; G C Visor; L H Lin; L Gu
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

5.  Overview of the stability and handling of recombinant protein drugs.

Authors:  J Geigert
Journal:  J Parenter Sci Technol       Date:  1989 Sep-Oct

6.  Stability of recombinant human epidermal growth factor in various solutions.

Authors:  F Araki; H Nakamura; N Nojima; K Tsukumo; S Sakamoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1989-02       Impact factor: 1.645

7.  The stability of cyclophosphamide in lyophilized cakes. Part I. Mannitol, lactose, and sodium bicarbonate as excipients.

Authors:  T R Kovalcik; J K Guillory
Journal:  J Parenter Sci Technol       Date:  1988 Jan-Feb

8.  Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide.

Authors:  C Oliyai; R T Borchardt
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

9.  Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor.

Authors:  J Bongers; E P Heimer; T Lambros; Y C Pan; R M Campbell; A M Felix
Journal:  Int J Pept Protein Res       Date:  1992-04

10.  Isolation and characterization of 101-beta-lysozyme that possesses the beta-aspartyl sequence at aspartic acid-101.

Authors:  H Yamada; T Ueda; R Kuroki; T Fukumura; T Yasukochi; T Hirabayashi; K Fujita; T Imoto
Journal:  Biochemistry       Date:  1985-12-31       Impact factor: 3.162

View more
  8 in total

1.  Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.

Authors:  David Ouellette; Chris Chumsae; Anca Clabbers; Czeslaw Radziejewski; Ivan Correia
Journal:  MAbs       Date:  2013-04-22       Impact factor: 5.857

2.  Mass Spectrometry Based Mechanistic Insights into Formation of Tris Conjugates: Implications on Protein Biopharmaceutics.

Authors:  Pradeep G Kabadi; Praveen Kallamvalliillam Sankaran; Dinesh V Palanivelu; Laxmi Adhikary; Anand Khedkar; Amarnath Chatterjee
Journal:  J Am Soc Mass Spectrom       Date:  2016-08-03       Impact factor: 3.109

3.  Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis.

Authors:  Soraya Hengsawas Surasarang; Galina Florova; Andrey A Komissarov; Sreerama Shetty; Steven Idell; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2017-11-10       Impact factor: 3.225

4.  Detection and quantitation of succinimide in intact protein via hydrazine trapping and chemical derivatization.

Authors:  Joshua J Klaene; Wenqin Ni; Joshua F Alfaro; Zhaohui Sunny Zhou
Journal:  J Pharm Sci       Date:  2014-07-14       Impact factor: 3.534

5.  Solid-state stability of human insulin. I. Mechanism and the effect of water on the kinetics of degradation in lyophiles from pH 2-5 solutions.

Authors:  R G Strickley; B D Anderson
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

6.  Bond cleavage reactions in solid aqueous carbohydrate solutions.

Authors:  L Streefland; A D Auffret; F Franks
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

7.  Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions.

Authors:  Jasmin F Sydow; Florian Lipsmeier; Vincent Larraillet; Maximiliane Hilger; Bjoern Mautz; Michael Mølhøj; Jan Kuentzer; Stefan Klostermann; Juergen Schoch; Hans R Voelger; Joerg T Regula; Patrick Cramer; Apollon Papadimitriou; Hubert Kettenberger
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

8.  Formulation Composition and Process Affect Counterion for CSP7 Peptide.

Authors:  Sawittree Sahakijpijarn; Chaeho Moon; John J Koleng; Robert O Williams
Journal:  Pharmaceutics       Date:  2019-09-29       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.